Scalper1 News
Although many say the drug industry is entering the “post-blockbuster era” as mega-sellers such as Lipitor lose their patents, there are drugs in the pipeline expected to pass the traditional blockbuster benchmark of $1 billion in global annual sales. Here’s a preview of four of them, expected to launch in the next 12 months, that have attracted much interest from Wall Street. Sovaldi: Gilead Sciences’ (GILD) hepatitis C treatment, formerly known Scalper1 News
Scalper1 News